Roivant Sciences completed a $200m investment in Immunovant.

Roivant Sciences, a healthcare company, completed a $200m investment in Immunovant, a clinical-stage biopharmaceutical company. “Roivant and Immunovant explored a range of possible transactions over the past few months, including a potential acquisition by Roivant of the minority interest in Immunovant, and ultimately agreed on this significant investment in order to support a robust development plan for IMVT-1401 and increase our stake in the company. We are incredibly excited about the prospects for IMVT-1401, and we are eager to support Immunovant through this investment. We look forward to continuing to work closely with Dr. Salzmann and the Immunovant management team to help develop IMVT-1401 to maximize benefit for patients with high levels of unmet medical need," Matt Gline, Roivant Sciences CEO.